3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 1/2
2
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
24
Carcinoma, Renal Cell
16
Stomach Neoplasms
9
Lung Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Carcinoma, Hepatocellular
6
Kidney Neoplasms
5
Brain Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Mesothelioma
4
Adenocarcinoma Of Esophagus
4
Skin Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Anus Neoplasms
3
Various Advanced Cancer
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Mesothelioma, Malignant
2
Liver Neoplasms
2
Hodgkin Disease
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma
2
Anal Canal Carcinoma
2
Adenocarcinoma
2
von Hippel-Lindau Disease
1
Interventions
Paclitaxel
30
Carboplatin
24
Cisplatin
11
Topotecan
8
liposomal doxorubicin
6
Hyperthermic Intraperitoneal Chemotherapy
6
mirvetuximab soravtansine
5
Cyclophosphamide
5
Drug Therapy
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
rucaparib
3
Peripheral Blood Stem Cell Transplantation
3
Neoadjuvant Therapy
3
Doxorubicin
3
Docetaxel
3
CP protocol
3
olaparib
2
liposomal amphotericin B
2
Surgical Procedures, Operative
2
Letrozole
2
Gemcitabine
2
trebananib
1
trastuzumab deruxtecan
1
phenoxodiol
1
pembrolizumab
1
oregovomab
1
niraparib
1
fluzoparib
1
epothilone B
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Ovarian Epithelial
×
Nivolumab
×
Clear all
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts